Pfizer Inc. will deprioritize development of its oral Janus kinase inhibitor Xeljanz (tofacitinib) in Crohn’s disease, ankylosing spondylitis and potentially psoriasis, the company announced Oct. 27 during its third quarter sales and earnings update.
Pfizer will focus further development of the drug on psoriatic arthritis and ulcerative colitis. Xeljanz has been approved since November...
Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.
Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.
Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.
The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.
The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.
Series B cash will be used to advance its Stargardt disease gene therapy.
